These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12145269)

  • 1. On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.
    Hinke SA; McIntosh CH; Hoffmann T; Kühn-Wache K; Wagner L; Bär J; Manhart S; Wermann M; Pederson RA; Demuth HU
    Diabetes Care; 2002 Aug; 25(8):1490-1; author reply 1491-2. PubMed ID: 12145269
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
    Holst JJ; Deacon CF
    Curr Opin Pharmacol; 2004 Dec; 4(6):589-96. PubMed ID: 15525549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide: the time is near.
    Huang A; Raskin P
    Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):249-51. PubMed ID: 15569268
    [No Abstract]   [Full Text] [Related]  

  • 4. On the treatment of diabetes mellitus with glucagon-like peptide-1.
    Holst JJ; Deacon C; Toft-Nielsen MB; Bjerre-Knudsen L
    Ann N Y Acad Sci; 1998 Dec; 865():336-43. PubMed ID: 9928027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
    Demuth HU; Hinke SA; Pederson RA; McIntosh CH
    Biochem Biophys Res Commun; 2002 Aug; 296(2):229-32. PubMed ID: 12163006
    [No Abstract]   [Full Text] [Related]  

  • 6. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
    Göke B; Hoppe B; Konrad A; Schirra J
    Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
    [No Abstract]   [Full Text] [Related]  

  • 7. Theratechnologies expands peptide portfolio in endocrinology.
    Walczak IM
    Diabetes Technol Ther; 2002; 4(5):734. PubMed ID: 12458565
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
    Meier JJ; Gallwitz B; Nauck MA
    BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of insulin secretagogues in the treatment of type 2 diabetes.
    Luna B; Hughes AT; Feinglos MN
    Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease].
    Ahrén B
    Lakartidningen; 2005 Feb 21-27; 102(8):545-9. PubMed ID: 15786905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
    Rachman J
    Diabet Med; 2004 Jan; 21 Suppl 1():18-20. PubMed ID: 15088933
    [No Abstract]   [Full Text] [Related]  

  • 12. [The role of incretins. Type 2 diabetes with new beginnings].
    MMW Fortschr Med; 2005 Mar; 147(10):48-9. PubMed ID: 15803785
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Association for the Study of Diabetes Annual Meeting, 1998. Treatment of type 2 diabetes and the pathogenesis of complications.
    Bloomgarden ZT
    Diabetes Care; 1999 Jul; 22(7):1209-15. PubMed ID: 10388992
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
    Thondam SK; Cross A; Cuthbertson DJ; Wilding JP; Daousi C
    Diabet Med; 2012 Aug; 29(8):e205-10. PubMed ID: 22486277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?
    Wu T; Thazhath SS; Bound MJ; Jones KL; Horowitz M; Rayner CK
    Diabetes Res Clin Pract; 2014 Oct; 106(1):e3-6. PubMed ID: 25172519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel "second-generation" approaches for the control of type 2 diabetes.
    Rotella DP
    J Med Chem; 2004 Aug; 47(17):4111-2. PubMed ID: 15293978
    [No Abstract]   [Full Text] [Related]  

  • 19. A gut response. The next generation of type 2 drugs.
    Kordella T
    Diabetes Forecast; 2004 Apr; 57(4):39-42. PubMed ID: 15119299
    [No Abstract]   [Full Text] [Related]  

  • 20. Research advances in the treatment of type 2 diabetes mellitus.
    Caro J; Wishner KL
    Int J Clin Pract Suppl; 1999 Sep; 107():23-33. PubMed ID: 10692729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.